Skip to main content
Premium Trial:

Request an Annual Quote

Ultivue: Richard Malabre

Ultivue, a company specializing in multiplex biomarker assays for tissue phenotyping and digital pathology, has appointed Richard Malabre as CFO. Malabre most recently was vice president and controller at Oxford Immunotec, which was acquired this year by PerkinElmer. Prior to Oxford Immunotec, he held the position of controller and other senior financial roles at firms including Salient Surgical Technologies, Neurometrix, and Teradyne.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.